Biotechnology Regenerative Medicine Law In Ukraine.

1. Introduction

Regenerative medicine is an important branch of modern biotechnology that focuses on repairing, replacing, or regenerating damaged human cells, tissues, and organs. It includes stem-cell therapy, tissue engineering, cellular therapies, regenerative biomaterials, gene-based treatments, and other advanced biomedical technologies.

In Ukraine, regenerative medicine is regulated through a combination of legislation governing healthcare, medicinal products, transplantation, biomedical research, human rights, biological materials, and medical professional licensing.

Unlike jurisdictions that have established a comprehensive, independent legal framework for Advanced Therapy Medicinal Products (ATMPs), Ukraine's regulatory approach is distributed across several legal instruments.

The central legal question is how Ukraine balances:

Scientific innovation and biotechnology research.

Patient safety and informed consent.

Ethical use of human cells and tissues.

Licensing and authorization of medical institutions.

Commercialization of regenerative treatments.

Liability for experimental or ineffective therapies.

Protection of genetic and medical information.

Important legal distinction: Not every stem-cell procedure is legally classified as transplantation, and not every regenerative treatment is automatically an authorized medicinal product. Its legal classification depends on the material used, manufacturing process, intended purpose, and manner of administration.

2. Constitutional and legislative foundations

The Ukrainian Constitution provides the fundamental legal basis for regenerative medicine.

Article 3 – Human dignity and life

Human life, health, dignity, and security are recognized as important social values. Biomedical research and regenerative procedures must respect human dignity.

Article 28 – Human dignity and consent

No person may be subjected to medical, scientific, or other experiments without free consent.

This is particularly important for experimental stem-cell treatments, gene modification, and tissue-engineering procedures.

Article 49 – Right to healthcare

The Constitution recognizes the right to healthcare and medical assistance. The state has responsibilities concerning the protection of public health and access to medical services.

Other important legislation includes:

Law of Ukraine on Fundamentals of Health Legislation.

Law of Ukraine on Medicinal Products.

Law of Ukraine on Application of Transplantation of Anatomical Materials to Humans.

Law of Ukraine on Protection of Personal Data.

Law of Ukraine on Scientific and Scientific-Technical Activities.

Law of Ukraine on Licensing of Types of Economic Activities.

Law of Ukraine on State Financial Guarantees of Medical Care.

These laws collectively influence regenerative medicine research, clinical application, commercialization, and patient protection.

3. Regulation of stem-cell therapy

Stem-cell therapy is one of the most important areas of regenerative medicine.

It involves using stem cells to repair damaged tissues, restore biological functions, or support the treatment of certain diseases.

Common categories include:

Embryonic stem cells.

Adult stem cells.

Mesenchymal stem cells.

Hematopoietic stem cells.

Induced pluripotent stem cells.

Umbilical-cord-derived stem cells.

Relevant legislation:

The Law of Ukraine No. 2427-VIII of 17 May 2018, On Application of Transplantation of Anatomical Materials to Humans, is particularly important.

Article 1 defines anatomical materials broadly, including human or animal cells and tissues.

Article 3 establishes the scope of the transplantation legislation and identifies important exclusions, including autotransplantation, implantation, and the removal of anatomical materials for diagnostic and scientific research.

Article 13 establishes that transplantation must be based on medical indications, applicable healthcare standards, and the informed consent of the recipient, subject to statutory exceptions.

The legislation also addresses the procurement and use of hematopoietic stem cells.

on May 17, 2018 № 2427-VIII+1

Legal significance

A regenerative treatment involving human cells must be classified correctly. For example:

A bone-marrow-derived hematopoietic stem-cell transplant may fall within transplantation legislation.

A procedure using a patient's own cells may fall within the statutory autotransplantation exclusion.

A cell-based product manufactured and administered as a medicinal product may require medicinal-product authorization and clinical-trial compliance.

The legal classification cannot be determined merely by calling a procedure a stem-cell treatment.

4. Regulation of tissue engineering and bioimplants

Tissue engineering combines biological cells, scaffolds, biomaterials, and engineering techniques to create or repair biological structures.

Examples include:

Artificial skin.

Regenerative cartilage.

Bone substitutes.

Tissue-engineered vascular structures.

Biological wound-healing materials.

Regenerative dental materials.

Ukraine's transplantation legislation expressly recognizes bioimplants made from human anatomical materials.

The 2018 transplantation law therefore becomes relevant when human anatomical materials are obtained for manufacturing bioimplants.

The legal framework also requires attention to the distinction between:

Human-derived biological materials.

Synthetic biomaterials.

Medical devices.

Biological medicinal products.

Tissue-engineered products.

Each category may have different authorization, manufacturing, safety, and quality-control requirements.

on May 17, 2018 № 2427-VIII+1

5. Regulation of advanced therapy medicinal products (ATMPs)

Advanced Therapy Medicinal Products include innovative medicinal products based on:

Gene therapy.

Somatic-cell therapy.

Tissue-engineered products.

These products present particular regulatory challenges because they may involve living cells, genetic modification, complex manufacturing procedures, and patient-specific biological materials.

Ukraine has taken steps towards developing specific regulatory requirements for advanced therapy clinical trials.

An important instrument is the Ministry of Health guideline:

ST-N MOHU 42-9.1:2024 – Requirements for the dossier of investigational advanced therapy medicinal products within clinical trials.

This guideline, effective from 12 November 2024, addresses documentation concerning the biological and pharmaceutical quality of investigational advanced therapy products.

It is particularly relevant to:

Cell-based medicinal products.

Gene-therapy investigations.

Tissue-engineered medicinal products.

Manufacturing quality.

Product characterization.

Clinical-trial authorization.

Державний експертний центр МОЗ України+1

Legal importance: This development provides a more specialized technical framework for advanced therapies. However, the existence of an ATMP guideline does not mean that Ukraine has adopted an identical regulatory system to the European Union's ATMP Regulation.

6. Clinical trials and experimental regenerative treatments

Clinical trials are essential for determining whether regenerative treatments are safe and effective.

Ukraine regulates clinical trials through medicinal-product legislation and Ministry of Health regulations.

Important instruments include:

Law of Ukraine on Medicinal Products.

Ministry of Health Order No. 690 of 23 September 2009.

Good Clinical Practice requirements.

Relevant ethics committee procedures.

Preclinical testing requirements.

The State Expert Center of the Ministry of Health plays an important role in the regulatory assessment of clinical trials.

Державний експертний центр МОЗ України+2

Important legal requirements

A regenerative medicine clinical trial should address:

Scientific justification.

Preclinical safety evidence.

Clinical-trial authorization.

Independent ethical review.

Informed consent.

Adverse-event reporting.

Medical monitoring.

Accurate clinical documentation.

Quality control of biological materials.

Article 45 of the Law on Fundamentals of Health Legislation is particularly important.

It permits medical and biological experiments on humans for socially beneficial purposes when they are scientifically justified, appropriately transparent, and based on full information and voluntary consent from a competent adult participant.

It also requires the possible benefits of an experiment to outweigh the risk of serious consequences for health or life.

zakon.rada.gov.ua+1

7. Regulation of biological samples and biobanks

Regenerative medicine depends on the collection, storage, testing, processing, and use of biological materials.

Examples include:

Stem-cell samples.

Tissue samples.

Blood-derived cellular materials.

Genetic materials.

Umbilical-cord-derived samples.

Biological specimens collected during surgery.

An important development is Cabinet of Ministers Resolution No. 999 of 30 August 2024, approving the procedure for collection, storage, and use of human biological samples for research purposes.

This framework addresses biobanking and research-related biological samples.

However, it expressly distinguishes research biobanking from clinical treatment and transplantation. It does not itself authorize a biobank to administer experimental stem-cell treatment.

The procedure also distinguishes its scope from activities involving umbilical cord blood stem-cell banks, clinical trials, bioimplant manufacturing, and transplantation.

9189675.fs1.hubspotusercontent-na1.net+1

Legal implications

A biobank should establish appropriate procedures concerning:

Lawful collection of samples.

Consent and information provided to donors.

Sample identification and traceability.

Secure storage.

Access controls.

Research-purpose limitations.

Protection of associated personal data.

Transfer and sharing of samples.

The Law on Protection of Personal Data is relevant where biological samples are associated with identifiable individuals.

8. Ethical regulation and human dignity

Regenerative medicine raises serious ethical questions because it can involve the manipulation of human cells, embryonic materials, genetic information, and biological identity.

The main ethical principles are:

A. Informed consent

Patients must understand:

The nature of the regenerative procedure.

Whether the treatment is experimental.

Possible medical complications.

Alternative treatments.

Expected benefits and uncertainties.

The possibility of treatment failure.

Articles 39 and 43 of the Fundamentals of Health Legislation are particularly relevant to patient information and consent.

B. Protection of human embryos

Research involving embryonic material raises additional ethical and legal questions concerning human dignity, reproductive rights, and permissible biomedical experimentation.

C. Non-commercial exploitation

The use of human anatomical materials must comply with applicable donation and transplantation rules. Commercial arrangements cannot simply override statutory requirements governing procurement and use.

D. Scientific integrity

Researchers must avoid fabricated clinical results, misleading therapeutic claims, and unsupported promises of permanent tissue regeneration.

9. Licensing and regulatory supervision

Regenerative medicine providers must comply with the licensing requirements applicable to their activities.

Depending on the procedure, this may involve:

A healthcare institution's medical-practice licence.

Authorization to conduct clinical trials.

Compliance with transplantation requirements.

Appropriate pharmaceutical manufacturing authorization.

Medical-device conformity requirements.

Qualified healthcare personnel.

Appropriate laboratory and storage facilities.

Relevant regulatory institutions include:

InstitutionRegulatory responsibility
Ministry of Health of UkraineHealthcare policy and regulatory framework
State Expert CenterClinical-trial and medicinal-product expertise
State Medical ServiceRelevant state supervision and control functions
National Transplantation CommitteeProfessional consultation and recommendations in transplantation
Healthcare ethics committeesEthical review of clinical research

The precise authority depends on the activity and applicable legislation.

10. Patient rights and medical liability

Regenerative medicine may involve serious complications, including:

Immune rejection.

Infection.

Abnormal cell growth.

Tumour formation.

Tissue damage.

Unintended immune reactions.

Failure of the transplanted material.

Long-term adverse effects.

Healthcare providers may face civil, administrative, or criminal liability depending on the circumstances.

Potential legal grounds include:

Medical negligence.

Treatment without valid informed consent.

Unauthorized medical experimentation.

Improper procurement or handling of human anatomical materials.

Misrepresentation of treatment effectiveness.

Breach of confidentiality.

Failure to report serious adverse events.

Articles 1166 and 1167 of the Civil Code of Ukraine are relevant to compensation for property and non-property damage.

Article 1195 is relevant to compensation for injury to health.

Article 140 of the Criminal Code concerns improper performance of professional duties by medical or pharmaceutical workers where the statutory elements are established.

11. Case laws and judicial interpretation

Relevant judicial authorities

An important qualification is necessary: there is relatively limited reported Ukrainian and European human-rights case law directly deciding the scientific efficacy or authorization of regenerative stem-cell therapies. The following cases are relevant because they establish legal principles concerning consent, bodily integrity, medical responsibility, and unlawful cellular-material practices.

Case 1. Arskaya v. Ukraine (2013)

European Court of Human Rights · Application No. 45076/05 · Judgment of 5 December 2013

Facts and legal issues

The case concerned medical treatment and the responsibilities of healthcare authorities in relation to a patient's medical condition and consent.

The European Court considered the relationship between medical intervention, patient autonomy, and the state's obligations under the European Convention on Human Rights.

Legal principles

The case is relevant to regenerative medicine because:

Medical interventions must respect patient autonomy.

Consent must be assessed in light of the patient's circumstances.

States must maintain appropriate safeguards concerning medical treatment.

Medical necessity and procedural safeguards are important when intervention occurs without consent.

Application to regenerative medicine

A hospital administering experimental stem-cell treatment cannot rely merely on a patient's general willingness to receive treatment. The patient must receive meaningful information about the particular intervention.

BAILII+2

Case 2. Mayboroda v. Ukraine (2023)

European Court of Human Rights · Application No. 14709/07 · Judgment of 13 April 2023

Facts

The applicant underwent emergency surgery during which her kidney was removed. Although she had agreed to surgery, she had not been informed about the possible kidney removal.

She subsequently discovered that the kidney had been removed without adequate disclosure.

Legal issue

Whether Ukraine had adequately protected the patient's right to informed consent under Article 8 of the European Convention on Human Rights.

Judgment

The European Court found a violation of Article 8.

It identified shortcomings in the regulatory framework and institutional safeguards governing informed consent and medical recordkeeping.

Application to regenerative medicine

This judgment has considerable relevance to:

Stem-cell transplantation.

Regenerative surgical procedures.

Tissue implantation.

Experimental cell therapies.

Procedures involving substantial changes to human biological material.

A patient should be informed about significant foreseeable interventions rather than being asked to provide excessively broad or vague consent.

HUDOC+2

Case 3. Institute of Cell Therapy investigation – Kyiv (2013)

Pechersky District Court of Kyiv · Case No. 757/22528/13-к · Court ruling dated 16 October 2013

Facts

The criminal investigation concerned allegations involving a private cellular-therapy institution.

The investigative materials described alleged unauthorized transplantation involving stem cells obtained from umbilical-cord blood and placental materials, together with questions concerning donor consent, handling of anatomical materials, and commercial activity.

The investigation also considered whether the institution had the legal status required under the transplantation legislation then in force.

Legal significance

The case illustrates the importance of:

Lawful procurement of biological materials.

Donor authorization and consent.

Proper institutional licensing.

Lawful storage and use of stem cells.

Compliance with transplantation legislation.

Important qualification

This was a procedural judicial ruling connected with an investigation. It should not be represented as a final conviction or a definitive judicial determination that all allegations were proven.

Application

It is a particularly relevant Ukrainian judicial document for understanding the regulatory risks associated with commercial stem-cell banks and regenerative medicine providers.

case № 757/22528/13-к

Case 4. Yuriy Volkov v. Ukraine

European Court of Human Rights · Application No. 45872/06 · Judgment of 19 December 2013

Legal principle

The Court considered bodily integrity as part of private life protected under Article 8 of the European Convention on Human Rights.

It emphasized that compulsory medical interventions require a lawful basis and must satisfy the Convention's requirements.

Application

This principle is relevant when patients are subjected to cell extraction, tissue harvesting, or regenerative interventions without legally valid consent.

HUDOC

12. European Convention and international biotechnology standards

Ukraine's regenerative medicine framework should also be examined in the context of international biomedical standards.

Important instruments include:

A. European Convention on Human Rights

Article 2 protects the right to life.

Article 3 prohibits torture and inhuman or degrading treatment.

Article 8 protects private life and bodily integrity.

These provisions can apply to serious violations involving experimental medical treatment.

B. Oviedo Convention

The Convention on Human Rights and Biomedicine establishes international principles concerning human dignity, informed consent, and biomedical research.

An important legal qualification is that Ukraine signed the Oviedo Convention in 2002 but has not ratified it, according to the material considered by the European Court in Spivak v. Ukraine (2025). It should therefore not be described as a ratified and binding treaty obligation for Ukraine.

BAILII

C. Good Clinical Practice

Good Clinical Practice establishes standards for ethical and scientifically reliable clinical trials.

Ukraine's State Expert Center publishes the applicable national clinical-trial framework and guidance, including updated GCP guidance.

Державний експертний центр МОЗ України+1

13. Regulation of regenerative medicine commercialization

Commercialization involves transforming scientific discoveries into medical products and services.

Examples include:

Commercial stem-cell banks.

Tissue-engineered products.

Regenerative skin products.

Gene-therapy products.

Cellular medicinal products.

Bioprinted tissues.

Commercial operators must distinguish between research services, medical treatment, transplantation, and the manufacture or sale of medicinal products.

A company cannot avoid applicable healthcare regulation merely by describing its treatment as a wellness service or biological innovation.

The regulatory requirements may include product registration, clinical-trial approval, manufacturing standards, quality assurance, and advertising compliance.

14. Data protection and genetic privacy

Regenerative medicine frequently requires processing sensitive personal information.

Examples include:

DNA sequences.

Genetic predisposition.

Stem-cell donor information.

Tissue compatibility results.

Medical histories.

Clinical-trial records.

Biological sample identification.

Ukraine's Law on Protection of Personal Data is relevant to the collection, processing, storage, and disclosure of personal data.

Healthcare providers must also respect medical confidentiality under the Fundamentals of Health Legislation.

This becomes especially important when Ukrainian biological samples are transferred to foreign research institutions or international biotechnology companies.

15. Recent regulatory developments

Several developments are particularly important for understanding Ukraine's current regenerative medicine framework.

DevelopmentLegal significance
Resolution No. 999 of 2024Research biobanking and biological samples
ATMP guideline ST-N MOHU 42-9.1:2024Documentation for investigational advanced therapies
Law No. 4203-IX of 2025Amendments to transplantation legislation
Resolution No. 203 of 2025Procurement, storage, testing, processing and use of anatomical materials for tissue transplantation
GCP guideline ST-N MOHU 42-7.18:2025Updated Good Clinical Practice requirements

These developments demonstrate increasing specialization in Ukraine's biotechnology and transplantation regulation.

9189675.fs1.hubspotusercontent-na1.net+4

16. Major legal challenges

Ukraine faces several important challenges in developing regenerative medicine.

1. Experimental treatment versus authorized treatment

Patients may have difficulty distinguishing clinically established therapies from experimental procedures.

2. Stem-cell tourism

Foreign patients may be attracted to treatments advertised as innovative, even when their clinical effectiveness has not been established.

3. Biological material ownership

Questions arise concerning control, storage, withdrawal of consent, and permissible future use of donated biological materials.

4. Long-term safety monitoring

Some regenerative treatments may produce complications years after administration.

5. Commercial exploitation

Private institutions may face conflicts between financial interests and patient safety.

6. Regulatory harmonization

Ukraine's biotechnology legislation needs continued alignment with relevant European regulatory standards.

7. Wartime healthcare conditions

Damage to laboratories, hospitals, supply chains, and research infrastructure creates additional challenges for the preservation and safe handling of biological materials.

17. Hypothetical legal examples

SituationRelevant legal issue
A clinic administers unapproved stem-cell treatmentMedicinal-product and medical-practice compliance
A hospital uses donated cells without valid authorizationTransplantation and consent requirements
A laboratory improperly stores stem cellsLicensing, quality and potential civil liability
A patient suffers injury after experimental therapyInformed consent and medical liability
A company sells tissue-engineered productsMedicinal-product or medical-device classification
A research institution transfers genetic samples abroadData protection and lawful sample transfer

These examples illustrate possible legal issues; the precise legal outcome depends on the facts and applicable statutory classification.

18. Conclusion

Regenerative medicine law in Ukraine is a developing area of biotechnology regulation. It combines constitutional protections, healthcare legislation, transplantation law, medicinal-product regulation, clinical-trial standards, ethical safeguards, and personal-data protection.

The Law of Ukraine No. 2427-VIII of 2018 provides an important legal foundation for transplantation and the handling of human anatomical materials. The Fundamentals of Health Legislation establish essential safeguards concerning medical experiments, consent, and patient protection.

The introduction of advanced therapy medicinal-product guidance in 2024, together with the development of biobanking regulation and subsequent transplantation reforms, demonstrates the growing importance of specialized biotechnology governance.

The cases of Arskaya v. Ukraine, Mayboroda v. Ukraine, and the 2013 Kyiv Institute of Cell Therapy investigation provide useful legal guidance concerning informed consent, bodily integrity, and the lawful handling of human cellular materials.

Ultimately, Ukraine's regenerative medicine framework must ensure that scientific innovation does not undermine human dignity, patient safety, medical accountability, or the lawful use of biological materials.

19. Important legal references and research sources

For academic research, the following primary and institutional sources are particularly useful.

Law No. 2427-VIII of 2018 – Transplantation of Anatomical Materials to Humans.

Fundamentals of Health Legislation of Ukraine.

Ukrainian medicinal-products legislation – State Expert Center.

Advanced Therapy Medicinal Products guideline, 2024.

Cabinet Resolution No. 999 of 2024 – Biological Samples.

Ukraine's 2025 transplantation-sector implementation report.

Mayboroda v. Ukraine – ECHR judgment.

Arskaya v. Ukraine – ECHR judgment.

Kyiv Institute of Cell Therapy – Court ruling, 2013.

Academic research note: The cases discussed above are relevant authorities on medical consent, bodily integrity, and cellular-material regulation, rather than judgments establishing the clinical effectiveness of regenerative therapies. This distinction is important when preparing a dissertation, research paper, or comparative biotechnology law study.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT